Prevalence of Thrombosis in COVID-Patients

Prevalence of Thrombosis in COVID-Patients in Correlation to Humoral and Cellular Immunity

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04615026

Enrollment

525

Registered

2020-11-04

Start date

2020-11-04

Completion date

2021-06-30

Last updated

2022-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

Examination of the prevalence of thrombosis in COVID-patients, especially in an out-patient setting. Assessment by duplex sonography. If thrombosis is detected, we will correlate it with immunity status. Assessment of health issues and cognitive function as late complication after infection.

Interventions

DIAGNOSTIC_TESTduplex sonography

all patients with consent receive a duplex ultrasound, blood test, cognitive test and test of smelling

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* SARS CoV 2 positive swap, at least 4 weeks after infection

Exclusion criteria

* under 18 years old no consent anemia

Design outcomes

Primary

Measure	Time frame
prevalence of thrombosis	20 minutes

Secondary

Measure	Time frame
correlation to immunity	20 minutes
Assessment of late complications	20 minutes

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026